Galmed Pharmaceuticals Ltd. (GLMD) Form 424B3 — Jun 8, 2026
Galmed Pharmaceuticals (GLMD) has entered into a definitive agreement to acquire Colospan Ltd., an Israeli medical device company, for a total consideration of approximately $4.5 million. The deal consists of $2.5 million in cash and $2.0 million in Galmed ordinary shares, with the share component valued based on the five-day average closing price prior to closing. Colospan develops the CG-100, a single-use intraluminal bypass device designed to prevent anastomotic leakage in colorectal surgery. The device holds CE Marking in Europe and Breakthrough Device designation from the FDA, with a pivotal trial currently underway in the U.S.
Key figures
- Offering Price
- 0.7
- Shares Offered
- 7500000
- Cash Consideration
- 2500000
- Stock Consideration
- 2000000
- Investment Commitment
- 6000000
- Tams Usd
- 6000000000
- Device Asp Usd
- 6000
- Escrow Percentage
- 7.5%
- Lockup Period Months
- 24
- Max Ownership Blocker
- 4.99%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.